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Abstract 
The present study investigated the effects of levodopa,  a precursor of dopamine (DA) 
therapeutically used for the treatment of Parkinson’s disease, on DA transport in the 
two different systems, COS-7 cells heterologously expressing rat monoamine 
transporter cDNA and in monoaminergic cell lines PC12 and SK-N-SH. Levodopa 
enhanced uptake of [3H]DA and [3H]norepinephrine (NE) but not [3H]serotonin in  the 
transfected COS-7 cells in a concentration-dependent manner. On the other hand, in 
PC12 and SK-N-SH cells where NET is functionally expressed, levodopa enhanced 
[3H]DA and [3H]NE uptake at low concentrations and inhibited the uptake at higher 
concentrations. The effects of levodopa on catecholamine transporters in the opposite 
direction suggest a different mechanism at the intra- and extracellular sites in a 
levodopa transport-dependent and independent manner. 
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Introduction 
Levodopa (L-DOPA), a precursor of dopamine (DA), is used for the treatment of 
Parkinson’s disease (PD) in order to compensate for the decreased dopaminergic 
function (Horykiewicz and Kish, 1987; Steiger and Quinn 1995). In early or middle 
stages of PD, remaining DA neurons require newly synthesized DA to support the 
altered dopaminergic activity. The DA from levodopa should be stored in synaptic 
vesicles for subsequent release, resulting in the activation of dopaminergic synaptic 
transmission. Therefore, it is vital to explore the relation between DA and levodopa 
transport in the remaining DA neurons.  
Levodopa is transported by amino acid transport systems, such as the L-system 
(Wade and Katzman, 1975; Anclus and Borchardt, 1986), and DA is transported by 
DAT (Iversen, 1971). Levodopa is not a transportable substrate for DAT, but transport 
of levodopa and DA through various transporters may affect each other within the cell 
in a direct or indirect manner. To answer this question, the present study explored the 
relationship between levodopa and DA transport in various cell systems expressing the 
monoamine neurotransmitter transporters. 
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Methods and Materials 
Cell culture 
Cell lines used were COS-7 (monkey kidney cells), SK-N-SH (human 
neuroblastoma cells), and PC12 (rat adrenal pheochromocytoma cells). All cells were 
cultured at 37 °C under 5 % CO2 / 95 % air. Culture medium was composed of 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % fetal calf 
serum (FCS), 100 unit/ml penicillin G, 100 µg/ml streptomycin and 0.25 µg/ml 
fungisone for COS-7 cells, minimal essential medium-alpha (αMEM) supplemented 
with 10 % fetal calf serum, 100 unit/ml penicillin G, 100 µg/ml streptomycin and 0.25 
µg/ml fungisone for SK-N-SH cells, DMEM supplemented with 5 % FCS, 10 % horse 
serum, 100 unit/ml penicillin G, 100 µg/ml streptomycin and 0.25 µg/ml fungisone for 
PC12 cells.  
Cell transfection 
COS-7 cells at subconfluence were harvested and transfected with cDNA by 
electroporation (Shimada et al., 1991; Kitayama et al., 1992; Sato et al., 2000). Parallel 
transfection with pcDNA3 vector alone was performed every time for the negative 
control. After electroporation, cells were diluted in the culture medium, plated in 24- or 
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48-well culture plates and cultured for 2-3 days. 
Uptake assay 
Cells were washed three times with oxygenated Krebs Ringer HEPES-buffered 
solution (KRH; 125 mM NaCl, 5.2 mM KCl, 1.2 mM CaCl2, 1.4 mM MgSO4, 1.2 mM 
KH2PO4, 5 mM glucose, 20 mM HEPES, pH 7.3±0.1) and incubated for 10 min at 37 
°C with [3H]DA or other radiolabeled ligands, as described previously (Kitayama et al., 
1992; Sato et al., 2000). After removal of excess radioligands by aspiration, the cells 
were washed three times rapidly with ice-cold KRH and any radioactivity remaining in 
the cells was extracted with NaOH and measured by liquid scintillation spectrometry. 
Nonspecific uptake was determined in the cells transfected with empty plasmid vector 
(mock) and also in each plate in the presense of 100 µM cocaine. For kinetic analysis, 
cells were incubated in KRH containing 10 nM [3H]DA and 0.1-100 µM cold DA. Data 
analyzed by Eadie-Hofstee plot using k.cat (BioMetallics). 
Statistical analyses were performed using analysis of variance (ANOVA) with 
pairwise comparison by Bonferroni method (Wallenstein et al., 1980). 
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Materials 
Drugs used were: levodopa (Wako Pure Chemical Industry Co., Ltd., Tokyo, 
Japan), cocaine hydrochloride (Takeda Chemical Industries, Ltd., Osaka, Japan), DA, 
pargyline hydrochloride (Nakalai Tesque, Kyoto, Japan), benserazide, 
m-hydroxybenzylhydrazine (HBH), OR486, 2-(-)-endoaminobicycloheptane- 
2-carboxylic acid (BCH) (Sigma Chemical Co., St. Louis, MO, USA).  
[3H]DA (1176.6 GBq/mmol), [3H]norepinephrine (NE) (462.5 GBq/mmol), and 
[3H]serotonin (5HT) (1028.6 GBq/mmol) were purchased from NEN Life Science 
Products, Inc. (Boston, MA, USA), and [3H]levodopa (814 GBq/mmol) from Moravek 
Biochemicals, Inc. (Brea, CA, USA). 
 
Results 
Effects of levodopa on dopamine uptake in COS-7 cells heterologously expressing 
monoamine transporter 
Initial examination of the effects of levodopa on DA transport was performed for 
COS-7 cells transfected with rat DAT cDNA. Simultaneous incubation with [3H]DA 
and levodopa increased the uptake of [3H]DA over [3H]DA alone, increasing with 
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incubation time (Fig. 1). The effect of levodopa was concentration-dependent (Fig. 2) 
and reversible (data not shown). Pretreatment with levodopa did not alter the 
facilitatory effect of levodopa (data not shown). Fig. 3 shows the kinetic analysis of the 
effect of levodopa on [3H]DA uptake. Levodopa increased Vmax value without 
affecting apparent affinity for DA (Km). 
 [3H]levodopa transport in COS-7 cells 
Next, we examined the transport of [3H]levodopa in COS-7 cells transfected with 
rat DAT cDNA or empty plasmid vector (mock-transfection). Fig. 4 clearly shows 
similar uptake of [3H]levodopa in both transfected cells, indicating that expression of 
DAT did not alter levodopa transport. This conclusion was supported by the finding 
that DAT inhibitor cocaine failed to affect the levodopa uptake (Fig. 4). On the other 
hand, a specific inhibitor of L-system amino acid transporter, BCH (Wade and 
Katzman, 1975; Audus and Brochardt 1986), significantly inhibited [3H]levodopa 
uptake (Fig. 4). 
Characterization of the effects of levodopa on dopamine transport in COS-7 cells 
To assess whether the effect of levodopa is specific for DAT, we examined the 
effect of levodopa on the transport of other monoamines in COS-7 cells heterologously 
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expressing rat NE transporter (NET) or 5HT transporter (SERT). Levodopa 
significantly enhanced [3H]NE uptake in COS-7 cells expressing rat NET, while it did 
not alter [3H]5HT uptake in COS-7 cells expressing rat SERT (Fig. 5). These results 
indicate that the effect of levodopa is specific for catecholamine transporters.  
To evaluate the one-way cross-talk between DA and levodopa, we examined the 
effect of an inhibitor of the levodopa-transportable L-system and inhibitors of levodopa 
metabolizing enzymes on the levodopa facilitation of [3H]DA uptake. BCH, an 
L-system inhibitor, did not affect [3H]DA uptake by itself, and did not affect the 
facilitatory action of levodopa on [3H]DA uptake (Fig. 6). Benserazide, an inhibitor of 
L-DOPA decarboxylase (DDC) (Lotti and Porter 1970; Goodale and Moore, 1976), 
slightly inhibited [3H]DA uptake by itself, and a facilitatory effect of levodopa on 
[3H]DA uptake was observed in the presence of benserazide (Fig. 7).  
m-Hydroxybenzylhydrazine (HBH), another inhibitor of DDC, did not eliminate the 
facilitatory effect of L-DOPA, although HBH by itself caused [3H]DA uptake inhibition 
(Fig. 7). OR486, an inhibitor of catechol-O-methyltransferase (COMT) (Nissinen et al., 
1988), did not alter the effect of levodopa on [3H]DA uptake (data not shown). 
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Effects of levodopa on dopamine uptake in SK-N-SH and PC12 cells 
Since the effect of levodopa was specific for catecholamine transporters, we further 
investigated the effect of levodopa in two cell lines which endogenously express human 
or rat NET. SK-N-SH cells derived from human neuroblastoma and PC12 cells derived 
from rat pheochromocytoma both reveal a significant uptake of [3H]DA as well as 
[3H]NE in a cocaine-sensitive manner (Greene and Tischler, 1976 Richards and Sadee 
1986). In both cells, levodopa significantly enhanced [3H]NE uptake at low 
concentrations (Fig. 8A). Interestingly, however, at higher concentrations levodopa 
inhibited [3H]NE uptake in a concentration-dependent fashion (Fig. 8A). A similar 
effect of L-DOPA on [3H]DA uptake was observed in SK-N-SH cells (data not shown). 
The inhibitory action of levodopa was more significant with longer incubation times 
(Fig. 8B). Pretreatment with levodopa and concomitant presence of levodopa with 
[3H]DA did not alter the inhibitory action of levodopa observed in simultaneous 
incubation with levodopa and [3H]DA. However, washout of cells after pretreatment 
with levodopa did not recover the [3H]DA uptake to control levels (data not shown). 
These results suggest that levodopa may enter the cell to exert its inhibitory action on 
[3H]DA uptake in these cell lines. 
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 [3H]levodopa transport in SK-N-SH cells 
To evaluate the possibility mentioned above, we examined the uptake of 
[3H]levodopa in SK-N-SH cells. Fig. 9 shows the uptake of [3H]levodopa in a 
BCH-sensitive fashion, similar to that observed in COS-7 cells (see Fig. 4). The 
time-course of [3H]levodopa uptake paralleled the inhibitory effect of levodopa on 
[3H]DA uptake as observed in Fig. 8B. 
 
Discussion 
The present study demonstrated that levodopa enhanced uptake of [3H]DA and 
[3H]NE but not [3H]5HT in COS-7 cells transfected with their transporter cDNA. 
Pharmacological characterization of the effects of levodopa suggests that levodopa acts 
on catecholamine transporters to facilitate their transport activity. This conclusion was 
supported by the finding that levodopa enhanced [3H]NE and [3H]DA uptake at low 
concentrations in PC12 and SK-N-SH cells where NET is functionally expressed. The 
failure of benserazide and HBH, inhibitors of AADC, to affect levodopa effects on DA 
transport suggest that metabolites of levodopa such as DA are not involved in this 
mechanism. The finding that BCH, an inhibitor of L-system, which is known to 
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transport levodopa, failed to affect DA uptake in COS cells expressing DAT also 
excludes the involvement of intracellular conversion of levodopa to DA.  
It is unclear of the precise mechanism underlying the facilitatory action of levodopa 
on DAT and NET in both COS-7 cells heterologously expressing catecholamine 
transporters and monoaminergic cell lines PC12 and SK-N-SH. Eshleman et al. (1997) 
demonstrated that COMT inhibitors potentiate the uptake of DA and NE but not 5HT in 
the cell lines heterologously expressing recombinant monoamine transporters, and 
proposed the hypothesis that prevention of the metabolism of DA to the more lipophilic 
3-methoxytyramine reduced its diffusion out of the cells, thereby resulting in apparent 
retention (uptake) of [3H]DA. L-DOPA is a substrate for COMT, so that it may inhibit 
COMT activity competitively for DA to produce an apparent potentiation of DA 
uptake. However, we believe this is not the case in our situation for the following 
reasons. First, OR-468, a COMT inhibitor, failed to affect [3H]DA uptake by itself, nor 
did it alter the facilitatory effect of levodopa on [3H]DA uptake in COS-7 cells 
expressing rat DAT. Second, the hypothesis proposed by Eshleman et al. (1997) is 
based on the idea that intracellular COMT activity metabolizes the [3H]DA taken up. 
However, BCH, an inhibitor of the levodopa-transportable L-system, failed to affect 
 13
the facilitatory effect of levodopa on [3H]DA uptake, indicating that levodopa did not 
necessarily enhance uptake by entering the cells. Although the inhibition of COMT by 
levodopa in its effect on [3H]DA uptake cannot be completely excluded, the present 
results suggest that levodopa by itself acts on the catecholamine transporters to 
facilitate their transport at least.  
 Higher concentrations of levodopa inhibited the uptake of [3H]DA in both PC12 
and SK-N-SH cells. This inhibition was greater at longer incubation times in 
association with a significant uptake of [3H]levodopa. Furthermore, washout of the 
cells pretreated with levodopa failed to recover the [3H]DA uptake to the control level. 
These results suggest that levodopa enters the cells, converts to DA, and thereby 
inhibits [3H]DA uptake. The cytosolic total DA concentration ([3H]DA plus DA 
synthesized from levodopa) becomes saturated at the lower extracellular [3H]DA 
concentrations. Intra- and extracellular metabolism of neurotransmitters, therefore, 
should be closely associated with transmitter transport through plasma membrane. It 
was demonstrated that NE metabolism by MAO or COMT changed with the activities 
of uptake1 and uptake2 for NE in neuronal and non-neuronal cells, respectively (see 
review of Trendelenburg, 1991). Blockade of vesicular storage has been found to alter 
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the kinetics of DA transport by synaptosomes (Parish and Shenk, 1996). We also found 
that inhibitors of vesicular monoamine transporter, such as reserpine, inhibited DA 
uptake, probably through the increase in cytosolic accumulation of DA (Hashimoto et 
al., unpublished observation). Therefore, increase in intracellular concentration is 
critical for the regulation of DAT transport activity. 
In summary, the present study demonstrated the effects of levodopa on 
catecholamine transporters in opposite directions, such as enhancement in COS cells 
expressing catecholamine transporter and in PC12 and SK-N-SH cells at low 
concentrations, and inhibition in PC12 and SK-N-SH cells at high concentrations. 
These results suggest the probability of different mechanism at the intra- and 
extracellular sites in a levodopa transport-dependent and -independent manner. 
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Figure legends 
 
Fig.1 Effects of L-DOPA and cocaine on the [3H]dopamine (DA) uptake in COS cells 
transfected with rat DA transporter (DAT) cDNA. Cells transfected with rat DAT cDNA 
were incubated with [3H]DA  in the presence (closed symbols) or absence (open 
symbols) of 100 µM L-DOPA. Total (circle) and nonspecific (triangle) uptake was 
determined in the absence or presence of 100 µM cocaine. Values represent mean±
SEM of 3 experiments each performed in triplicate. *P<0.05 compared with total 
uptake in the absence of L-DOPA. 
 
Fig.2 Concentration-response relationship of the facilitatory effects of L-DOPA on 
[3H]DA uptake in COS cells expressing rat DAT. Cells were incubated at 37 ℃ for 5 
min with 10 nM [3H]DA  in the presence or absence of various concentrations of 
L-DOPA. Specific uptake of [3H]DA  was expressed as % of control. Control uptake in 
the absence of L-DOPA was 136.4±33.1 fmol/well. Values represent mean±SEM of 3 
experiments each performed in triplicate. *P<0.05, **P<0.01 ***P<0.001 compared 
with control, respectively. 
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Fig.3 Changes in the kinetics of [3H]DA uptake induced by L-DOPA in COS cells 
expressing rat DAT. Cells were incubated at 37 ℃ for 5 min with 10 nM [3H]DA  and 
various concentrations of unlabeled DA (0.01-30 µM) in the presence (closed circle) or 
absence (open circle) of 100 µM L-DOPA. Representative results from single 
experiment performed in triplicate are shown. Km of [
3H]DA  uptake in the absence and 
presence of 100 µM L-DOPA was 2.51 ± 0.24 and 2.56 ± 0.16 (no significant 
difference, n=3~4), and Vmax was 119. 1 ± 6.3 and 158.4 ± 5.5 (P<0.05, n=3~4), 
respectively. 
 
Fig.4 Uptake of [3H]L-DOPA in COS-7 cells transfected with rat DAT cDNA or with 
empty plasmid vector (Mock). Cells were incubated with 10 nM [3H]L-DOPA in the 
presence or absence of 1 mM L-DOPA, 1 mM BCH or 100 µM cocaine. Values 
represent mean±SEM of 3 experiments each performed in triplicate. *P<0.001 
compared with total uptake.  
 
Fig.5 Effects of L-DOPA on the uptake of [3H]DA, [3H]norepinephrine (NE) and 
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[3H]serotonin (5HT) in COS cells expressing rat DAT, NE transporter (NET) or 5HT 
transporter (SERT). Cells transfected with cDNA of rat DAT NET or SERT were 
incubated at 37 ℃for 10 or 20 min with 10 nM [3H]DA, 20 nM [3H]NE or 20 nM 
[3H]5HT in the presence (striped bar) or absence (open bar) of 100 µM L-DOPA. 
Specific uptake was calculated by subtracting uptake in the presence of 100 µM 
cocaine from total uptake in the absence of cocaine and presented as % of control 
uptake measured at 10 min incubation (in the absence of L-DOPA). The control specific 
uptake of [3H]DA, [3H]NE and [3H]5HT was 69.0±3.1, 171.6±1.9 and 90.2±1.4 
fmol/well for 10 min incubation, respectively. Values represent mean±SEM of 3 
experiments each performed in triplicate determinations. *P<0.01compared with the 
uptake in the absence of L-DOPA. 
 
Fig.6 Effect of L-system inhibitor on levodopa-induced enhancement of [3H]DA uptake 
in COS-7 cells expressing rat DAT. Cells were incubated at 37 ℃ for 10 min with 10 
nM [3H]DA in the presence or absence of 100 µM L-DOPA and/or 1 mM BCH, an L 
system inhibitor. Specific uptake was determined by subtracting the nonspecific uptake 
in the presence of 100 µM cocaine and expressed as control uptake which was 101.1±
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4.4 fmol/well for 10 min incubation. Values represent mean±SEM of 3 experiments 
each performed in triplicate. *P<0.01 compared with control. 
 
Fig.7 Effects of inhibitors of aromatic amino acid decarboxylase (AADC) on 
levodopa-induced enhancement of [3H]DA uptake in COS-7 cells expressing rat DAT. 
Cells were incubated at 37 ℃ for 10 min with 10 nM [3H]DA in the presence or absence 
of 100 µM L-DOPA and/or 100 µM benserazide or 100 µM m-hydroxybenzylhydrazine 
(HBH), inhibitors of AADC. Values represent mean±SEM of 3 experiments each 
performed in triplicate. Control specific uptake of [3H]DA was 119.8±1.7 fmol/well 
for 10 min incubation. *P<0.05 compared with control or AADC inhibitor alone. 
 
Fig.8 Effects of L-DOPA on [3H]NE or [3H]DA uptake in SK-N-SH cells and PC12 
cells. A. Concentration-response relationship for the effects of L-DOPA on [3H]NE 
uptake in SK-N-SH cells and PC12 cells. Cells were incubated with 20 nM [3H]NE in 
the presence or absence of various concentrations of L-DOPA. Values represent mean
±SEM of 3 experiments each performed in triplicate and expressed as % of control in 
the absence of L-DOPA. Control specific uptake of [3H]NE in SK-N-SH cells and PC12 
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cells was 590.2±74.8 and 125.4±8.6 fmol/well for 10 min incubation, respectively. 
*P<0.05 compared with control. B. Time-course of the inhibitory effect of L-DOPA on 
[3H]DA uptake in SK-N-SH cells. Cells were incubated with 10 nM [3H]DA in the 
presence or absence of 100 µM L-DOPA. Values represent mean±S.E.M of 3 
experiments each performed in triplicate and were expressed as % of the control 
measured for 5 min incubation without L-DOPA, which was 98.4±15.4 fmol/well. 
*P<0.01 compared with control, respectively. 
 
Fig.9 [3H]L-DOPA uptake in SK-N-SH cells. Cells were incubated at 37 ℃ for various 
times with 10 nM [3H]L-DOPA in the presence or absence of 1 mM BCH, an L system 
inhibitor. Values represent mean±SEM of 3 experiments each performed in triplicate. 
*P<0.001 compared with the total uptake in the absence of BCH.  
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